Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FTLFNASDAQ:QNTMNASDAQ:SLNNASDAQ:TARA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFTLFFitLife Brands$14.58+4.1%$13.49$9.83▼$17.75$131.48M0.918,273 shs6,882 shsQNTMQuantum Biopharma$11.55-5.5%$7.77$2.70▼$18.00$31.25M0.111.00 million shs157,456 shsSLNSilence Therapeutics$5.06+4.5%$3.44$1.97▼$22.71$151.45M1.2300,604 shs66,744 shsTARAProtara Therapeutics$3.13-1.3%$3.83$1.60▼$10.48$120.76M1.73770,777 shs372,832 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFTLFFitLife Brands+4.14%+6.89%+8.64%-5.57%+4.14%QNTMQuantum Biopharma-5.48%+12.68%+68.12%+85.39%+1,154,999,900.00%SLNSilence Therapeutics+4.55%+15.79%+52.41%+5.64%-78.21%TARAProtara Therapeutics-1.26%-1.88%-25.48%-15.86%+4.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFTLFFitLife Brands4.3247 of 5 stars3.75.00.00.01.63.33.1QNTMQuantum BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ASLNSilence Therapeutics3.4659 of 5 stars4.44.00.00.02.81.70.6TARAProtara Therapeutics2.9711 of 5 stars4.61.00.00.03.90.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFTLFFitLife Brands 3.33Buy$20.5040.60% UpsideQNTMQuantum Biopharma 0.00N/AN/AN/ASLNSilence Therapeutics 2.71Moderate Buy$33.83568.64% UpsideTARAProtara Therapeutics 3.14Buy$20.50554.95% UpsideCurrent Analyst Ratings BreakdownLatest QNTM, TARA, SLN, and FTLF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025TARAProtara TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$21.005/9/2025SLNSilence TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$4.00 ➝ $3.005/9/2025SLNSilence TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$45.00 ➝ $25.005/9/2025SLNSilence TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $35.004/28/2025TARAProtara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.004/16/2025TARAProtara TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$12.003/17/2025FTLFFitLife BrandsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.003/14/2025TARAProtara TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight3/11/2025TARAProtara TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$22.003/7/2025SLNSilence TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.003/6/2025TARAProtara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFTLFFitLife Brands$63.86M2.14$0.77 per share19.05$3.04 per share4.80QNTMQuantum BiopharmaN/AN/AN/AN/A$21.29 per shareN/ASLNSilence Therapeutics$27.70M5.47N/AN/A$0.71 per share7.13TARAProtara TherapeuticsN/AN/AN/AN/A$6.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFTLFFitLife Brands$5.30M$0.8417.2513.25N/A13.38%28.03%15.13%N/AQNTMQuantum Biopharma-$17.90M-$15.98N/AN/AN/AN/A-84.21%-62.63%N/ASLNSilence Therapeutics-$53.82M-$1.50N/AN/AN/A-342.00%-62.81%-33.89%N/ATARAProtara Therapeutics-$40.42M-$1.72N/AN/AN/AN/A-55.96%-49.06%8/5/2025 (Estimated)Latest QNTM, TARA, SLN, and FTLF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025FTLFFitLife Brands$0.24$0.20-$0.04$0.20N/AN/A5/14/2025Q1 2025QNTMQuantum Biopharma-$0.37-$1.41-$1.04-$3.53$2.09 million$2.09 million5/8/2025Q1 2025SLNSilence Therapeutics-$0.18-$0.60-$0.42-$0.60$3.58 million$0.14 million5/8/2025Q1 2025TARAProtara Therapeutics-$0.47-$0.29+$0.18-$0.29N/AN/A3/28/2025Q4 2024QNTMQuantum Biopharma-$0.80-$2.89-$2.09-$2.89$0.92 millionN/A3/27/2025Q4 2024FTLFFitLife Brands$0.22$0.21-$0.01N/AN/AN/A3/12/2025Q4 2024TARAProtara Therapeutics-$0.57-$0.48+$0.09-$0.48N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFTLFFitLife BrandsN/AN/AN/AN/AN/AQNTMQuantum BiopharmaN/AN/AN/AN/AN/ASLNSilence TherapeuticsN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFTLFFitLife Brands0.281.500.64QNTMQuantum BiopharmaN/A3.763.76SLNSilence TherapeuticsN/A9.319.31TARAProtara TherapeuticsN/A9.859.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFTLFFitLife Brands2.32%QNTMQuantum Biopharma1.24%SLNSilence Therapeutics98.73%TARAProtara Therapeutics38.13%Insider OwnershipCompanyInsider OwnershipFTLFFitLife Brands61.30%QNTMQuantum Biopharma8.53%SLNSilence Therapeutics2.95%TARAProtara Therapeutics8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFTLFFitLife Brands209.39 million3.56 millionNot OptionableQNTMQuantum BiopharmaN/A2.71 million1.76 millionN/ASLNSilence Therapeutics10029.93 millionN/ANot OptionableTARAProtara Therapeutics3038.58 million18.05 millionOptionableQNTM, TARA, SLN, and FTLF HeadlinesRecent News About These CompaniesProtara Therapeutics (NASDAQ:TARA) Earns Buy Rating from Analysts at Jones TradingMay 24 at 11:53 AM | marketbeat.comBNP Paribas Financial Markets Purchases Shares of 151,906 Protara Therapeutics, Inc. (NASDAQ:TARA)May 24 at 3:29 AM | marketbeat.comJones Trading Initiates Coverage of Protara Therapeutics (TARA) with Buy RecommendationMay 23 at 6:58 PM | msn.comToronto Dominion Bank Takes Position in Protara Therapeutics, Inc. (NASDAQ:TARA)May 23 at 5:15 AM | marketbeat.comRichard Levy Spends US$64k On Protara Therapeutics StockMay 22 at 12:04 PM | finance.yahoo.comVelan Capital Investment Management LP Buys 1,005,000 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA)May 21 at 8:23 AM | marketbeat.comJanus Henderson Group PLC Invests $11.94 Million in Protara Therapeutics, Inc. (NASDAQ:TARA)May 19, 2025 | marketbeat.comWith 73% ownership, Protara Therapeutics, Inc. (NASDAQ:TARA) boasts of strong institutional backingMay 16, 2025 | finance.yahoo.comIntegral Health Asset Management LLC Makes New $7.39 Million Investment in Protara Therapeutics, Inc. (NASDAQ:TARA)May 14, 2025 | marketbeat.comJ. Goldman & Co LP Takes $748,000 Position in Protara Therapeutics, Inc. (NASDAQ:TARA)May 14, 2025 | marketbeat.comProtara Therapeutics to Participate in Upcoming Investor ConferencesMay 13, 2025 | globenewswire.comDriehaus Capital Management LLC Makes New Investment in Protara Therapeutics, Inc. (NASDAQ:TARA)May 12, 2025 | marketbeat.comProtara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Buy" from BrokeragesMay 12, 2025 | marketbeat.comBarclays PLC Takes $492,000 Position in Protara Therapeutics, Inc. (NASDAQ:TARA)May 11, 2025 | marketbeat.comProtara Therapeutics Reports Q1 2025 Financial ResultsMay 11, 2025 | tipranks.comProtara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business UpdateMay 8, 2025 | globenewswire.comBlackstone Inc. Purchases Shares of 1,680,000 Protara Therapeutics, Inc. (NASDAQ:TARA)May 8, 2025 | marketbeat.com5AM Venture Management LLC Takes Position in Protara Therapeutics, Inc. (NASDAQ:TARA)May 4, 2025 | marketbeat.comAcorn Capital Advisors LLC Makes New Investment in Protara Therapeutics, Inc. (NASDAQ:TARA)May 4, 2025 | marketbeat.comRenaissance Technologies LLC Sells 194,440 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA)May 4, 2025 | marketbeat.comRA Capital Management L.P. Buys 1,500,000 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA)May 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQNTM, TARA, SLN, and FTLF Company DescriptionsFitLife Brands NASDAQ:FTLF$14.58 +0.58 (+4.14%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$14.45 -0.13 (-0.89%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.Quantum Biopharma NASDAQ:QNTM$11.55 -0.67 (-5.48%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$11.73 +0.18 (+1.56%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.Silence Therapeutics NASDAQ:SLN$5.06 +0.22 (+4.55%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$5.07 +0.01 (+0.28%) As of 05/23/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.Protara Therapeutics NASDAQ:TARA$3.13 -0.04 (-1.26%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$3.19 +0.06 (+1.88%) As of 05/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
